Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (300534) - Net Assets
Based on the latest financial reports, Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (300534) has net assets worth CN¥813.96 Million CNY (≈ $119.11 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.42 Billion ≈ $207.85 Million USD) and total liabilities (CN¥606.47 Million ≈ $88.75 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Gansu Longshenrongfa Pharmaceutical Indu's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥813.96 Million |
| % of Total Assets | 57.3% |
| Annual Growth Rate | 22.54% |
| 5-Year Change | 6.58% |
| 10-Year Change | 10.99% |
| Growth Volatility | 72.97 |
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd - Net Assets Trend (2011–2025)
This chart illustrates how Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's net assets have evolved over time, based on quarterly financial data. See 300534 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (2011–2025)
The table below shows the annual net assets of Gansu Longshenrongfa Pharmaceutical Industry Co Ltd from 2011 to 2025. For live valuation and market cap data, see how much is Gansu Longshenrongfa Pharmaceutical Indu worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥781.08 Million ≈ $114.30 Million |
+7.30% |
| 2024-12-31 | CN¥727.93 Million ≈ $106.52 Million |
+2.31% |
| 2023-12-31 | CN¥711.51 Million ≈ $104.12 Million |
-6.76% |
| 2022-12-31 | CN¥763.13 Million ≈ $111.67 Million |
+4.13% |
| 2021-12-31 | CN¥732.84 Million ≈ $107.24 Million |
-0.85% |
| 2020-12-31 | CN¥739.13 Million ≈ $108.16 Million |
+0.03% |
| 2019-12-31 | CN¥738.88 Million ≈ $108.12 Million |
+2.50% |
| 2018-12-31 | CN¥720.83 Million ≈ $105.48 Million |
+1.21% |
| 2017-12-31 | CN¥712.19 Million ≈ $104.22 Million |
+1.20% |
| 2016-12-31 | CN¥703.74 Million ≈ $102.98 Million |
+73.52% |
| 2015-12-31 | CN¥405.57 Million ≈ $59.35 Million |
+11.70% |
| 2014-12-31 | CN¥363.10 Million ≈ $53.13 Million |
+13.85% |
| 2013-12-31 | CN¥318.92 Million ≈ $46.67 Million |
+86.00% |
| 2012-12-31 | CN¥171.46 Million ≈ $25.09 Million |
+278.11% |
| 2011-12-31 | CN¥45.35 Million ≈ $6.64 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2360.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥269.40 Million | 38.03% |
| Other Components | CN¥439.06 Million | 61.97% |
| Total Equity | CN¥708.45 Million | 100.00% |
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd Competitors by Market Cap
The table below lists competitors of Gansu Longshenrongfa Pharmaceutical Industry Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Metro Mining Ltd
AU:MMI
|
$337.38 Million |
|
Acme Electronics
TWO:8121
|
$337.54 Million |
|
A-LIVING SM.CI.SV. H YC 1
F:1V0
|
$337.61 Million |
|
Chengdu Huasun Group Inc Ltd
SHE:000790
|
$337.70 Million |
|
Chung Hwa Chemical Industrial Works Ltd
TW:1727
|
$337.30 Million |
|
Omni Bridgeway Ltd
AU:OBL
|
$337.13 Million |
|
Ascencio (D)
BR:ASCE
|
$337.05 Million |
|
Yangzhou Chenhua New Material Co Ltd
SHE:300610
|
$336.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 662,284,451 to 708,453,165, a change of 46,168,714 (7.0%).
- Net income of 43,950,794 contributed positively to equity growth.
- Dividend payments of 14,831,657 reduced retained earnings.
- Other factors increased equity by 17,049,578.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥43.95 Million | +6.2% |
| Dividends Paid | CN¥14.83 Million | -2.09% |
| Other Changes | CN¥17.05 Million | +2.41% |
| Total Change | CN¥- | 6.97% |
Book Value vs Market Value Analysis
This analysis compares Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.25x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 13.41x to 3.25x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.57 | CN¥7.60 | x |
| 2012-12-31 | CN¥1.34 | CN¥7.60 | x |
| 2013-12-31 | CN¥1.52 | CN¥7.60 | x |
| 2014-12-31 | CN¥1.60 | CN¥7.60 | x |
| 2015-12-31 | CN¥1.78 | CN¥7.60 | x |
| 2016-12-31 | CN¥2.86 | CN¥7.60 | x |
| 2017-12-31 | CN¥2.35 | CN¥7.60 | x |
| 2018-12-31 | CN¥2.38 | CN¥7.60 | x |
| 2019-12-31 | CN¥2.41 | CN¥7.60 | x |
| 2020-12-31 | CN¥2.39 | CN¥7.60 | x |
| 2021-12-31 | CN¥2.37 | CN¥7.60 | x |
| 2022-12-31 | CN¥2.46 | CN¥7.60 | x |
| 2023-12-31 | CN¥2.09 | CN¥7.60 | x |
| 2024-12-31 | CN¥2.18 | CN¥7.60 | x |
| 2025-12-31 | CN¥2.34 | CN¥7.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gansu Longshenrongfa Pharmaceutical Industry Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.20%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.96%
- • Asset Turnover: 0.64x
- • Equity Multiplier: 1.97x
- Recent ROE (6.20%) is below the historical average (8.43%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 30.76% | 10.42% | 1.11x | 2.67x | CN¥9.38 Million |
| 2012 | 14.73% | 11.88% | 0.72x | 1.72x | CN¥8.11 Million |
| 2013 | 12.83% | 14.88% | 0.61x | 1.42x | CN¥9.02 Million |
| 2014 | 16.64% | 20.04% | 0.63x | 1.32x | CN¥24.11 Million |
| 2015 | 14.96% | 21.88% | 0.43x | 1.59x | CN¥20.12 Million |
| 2016 | 6.71% | 17.52% | 0.35x | 1.08x | CN¥-23.12 Million |
| 2017 | 2.40% | 6.35% | 0.34x | 1.10x | CN¥-54.11 Million |
| 2018 | 1.70% | 6.04% | 0.26x | 1.08x | CN¥-59.81 Million |
| 2019 | 1.75% | 5.35% | 0.30x | 1.11x | CN¥-60.28 Million |
| 2020 | 0.25% | 0.72% | 0.29x | 1.19x | CN¥-71.10 Million |
| 2021 | -1.26% | -3.16% | 0.35x | 1.14x | CN¥-81.13 Million |
| 2022 | 5.20% | 4.85% | 0.88x | 1.22x | CN¥-35.82 Million |
| 2023 | 9.73% | 5.71% | 0.81x | 2.11x | CN¥-1.72 Million |
| 2024 | 3.90% | 2.48% | 0.74x | 2.12x | CN¥-40.42 Million |
| 2025 | 6.20% | 4.96% | 0.64x | 1.97x | CN¥-26.89 Million |
Industry Comparison
This section compares Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,819,786,107
- Average return on equity (ROE) among peers: 5.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (300534) | CN¥813.96 Million | 30.76% | 0.75x | $337.36 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $5.88 Billion | 7.12% | 1.83x | $612.18 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $536.15 Million | 4.62% | 0.32x | $371.95 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $0.00 | 0.00% | 0.00x | $4.52 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $13.64 Billion | 12.57% | 0.51x | $2.56 Billion |
| Wedge Industrial Co Ltd (000534) | $549.14 Million | 1.31% | 0.01x | $2.22 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $893.64 Million | 25.78% | 0.79x | $12.90 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $734.70 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $271.26 Million | 1.07% | 1.01x | $324.84 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $1.60 Billion | -10.44% | 3.72x | $929.28 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $9.75 Billion | 6.63% | 0.12x | $3.13 Billion |
About Gansu Longshenrongfa Pharmaceutical Industry Co Ltd
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD researches, develops, produces, and sells traditional Chinese medicines, medical devices, and health products in China and internationally. It is also involved in the cultivation, processing, and sales of chemical drugs and medicinal herbs, as well as pharmaceutical distribution, testing, and inspection services. The company was founded in 2002… Read more